Athena Pharmaceutiques Oral Dispersible Tablets

Athena Pharmaceutiques Oral Dispersible Tablets

X

Digital content for Inke S.A

INKE S.A

About, Contact Details

EVENTS

Webinars & Exhibitions

Webinars & Exhibitions

PRESENTATION(s)

Product List 2022, FDF Product List 2021, Corporate Presentation, GMP Certificate 2021

VIDEO(s)

No Video

DIGITAL CONTENT

25 News

25 News

APIs // Active Pharmaceutical Ingredients

45 APIs, 21 USDMF, 10 CEP/COS, 10 JDMF, 7 KDMF, 20 NDC API, 41 Listed APIs

DEVELOPMENTS

9 Drug(s) in Development

9 Drug(s) in Development

DOSSIERs // Finished Dosage Formulations

289 Dossiers, 289 Listed Dossiers

KEY PRODUCTS

Aclidinium Bromide, Arformoterol Tartrate, Clevidipine, Formoterol Fumarate, Glycopyrronium Bromide, Granisetron, Granisetron Hydrochloride, Indacaterol Acetate, Indacaterol Maleate, Olodaterol Hydrochloride, Revefenacin, Salmeterol Xinafoate, Tafamidis, Tafamidis Meglumine, Tiotropium Bromide, Umeclidinium Bromide, Vilanterol Trifenatate

Aclidinium Bromide
Arformoterol Tartrate
Clevidipine
Formoterol Fumarate
Glycopyrronium Bromide
Granisetron
Granisetron Hydrochloride
Indacaterol Acetate
Indacaterol Maleate
Olodaterol Hydrochloride
Revefenacin
Salmeterol Xinafoate
Tafamidis
Tafamidis Meglumine
Tiotropium Bromide
Umeclidinium Bromide
Vilanterol Trifenatate

SERVICES

All Services, API Manufacturing, API & Drug Product Development, Sales, Marketing, Registration

All Services
API Manufacturing
API & Drug Product Development
- 1 API Development
Sales, Marketing, Registration
- 1 Regulatory Affairs / Pharmacovigilance

INSPECTIONS & REGISTRATIONS

5 FDA, 10 EDQM, 1 GDUFA

Full View Screen

Full Screen View

Neuraxpharm completes its presence in Benelux by opening an affiliate

Neuraxpharm completes its presence in Benelux by opening an affiliate

PR NEWSWIRE

24 Jan 2023

Neuraxpharm launches European campaign to increase awareness of medical cannabis

Neuraxpharm launches European campaign to increase awareness of medical cannabis

PR NEWSWIRE

19 Oct 2022

Neuraxpharm to increase branded business through upcoming acquisition of established products from Sanofi

Neuraxpharm to increase branded business through upcoming acquisition of established products from Sanofi

PR NEWSWIRE

12 Jul 2022

Inke to triple capacity for inhalation API manufacturing

Inke to triple capacity for inhalation API manufacturing

PRESS RELEASE

20 Apr 2022

Panaxia & Neuraxpharm: First export of medical cannabis sublingual tab to France

Panaxia & Neuraxpharm: First export of medical cannabis sublingual tab to France

PR NEWSWIRE

24 Jan 2022

Neuraxpharm appoints commercial expert Dr. Maximilian von Wülfing COF

Neuraxpharm appoints commercial expert Dr. Maximilian von Wülfing COF

PRNEWSWIRE

01 Jun 2021

Corporate announcement: Update concerning novel coronavirus (COVID-19)

Corporate announcement: Update concerning novel coronavirus (COVID-19)

PRESS RELEASE

23 Mar 2021

Neuraxpharm establishes operations in the Republic of Ireland the acquisition

Neuraxpharm establishes operations in the Republic of Ireland the acquisition

PRNEWSWIRE

14 Dec 2020

Neuraxpharm acquires market-leading value-added product for emergency

Neuraxpharm acquires market-leading value-added product for emergency

PRNEWSWIRE

14 Sep 2020

Corporate announcement: COVID-19 update

Corporate announcement: COVID-19 update

PRESS RELEASE

23 Mar 2020

Contact Supplier

View Presentation

Neuraxpharma RM

Cosmoprof Worldwide

Not Confirmed

envelop Contact Supplier

Market Place

Home

Menu

Post Enquiry

Market Place

Search